侵袭性非伤寒型沙门氏菌疫苗景观:未来的创新和挑战
Nicole M Revie1, Matthew Y Guo1, Anne E Mullin1
1Shift Health, Toronto, Canada.
Vaccine
|February 17, 2026
概括
开发针对侵袭性非伤寒型沙门氏菌 (iNTS) 疾病的疫苗至关重要,特别是在撒哈拉以南非洲. 在将 iNTS 候选疫苗推向临床试验方面取得了重大进展,解决了关键的公共卫生需求.
科学领域:
- 全球健康 全球健康
- 传染性疾病 传染性疾病
- 疫苗学 疫苗学 疫苗学
背景情况:
- 侵袭性非伤寒型沙门氏菌 (iNTS) 疾病是撒哈拉以南非洲血流感染的主要原因.
- 与INTS疾病相关的高发病率和死亡率,目前没有获得许可的疫苗.
- 对有效的iNTS预防策略的重大未满足的医疗需求.
研究的目的:
- 审查在开发针对侵袭性非类型型沙门氏菌 (iNTS) 疾病的疫苗方面的进展和挑战.
- 突出INTS候选疫苗和平台技术的进展.
- 概述正在进行的全球卫生工作,以加快 iNTS 疫苗开发和部署.
主要方法:
- 审查目前的 iNTS 疫苗开发格局,包括临床和临床前阶段的候选疫苗.
- 对 iNTS 候选疫苗使用的各种平台技术的分析.
- 检查全球卫生倡议和战略,以支持 iNTS 疫苗的发展.
主要成果:
- 一些有前途的 iNTS 疫苗候选人已经进入临床开发阶段,其中一些正在进入第二阶段试验.
- 正在使用多种平台技术,包括那些具有更广泛的覆盖面对相关沙门氏菌血清病毒的潜在覆盖范围.
- 全球卫生组织通过首选产品特性和价值评估,积极支持发展.
结论:
- 在INTS疫苗开发方面取得了实质性的进展,多个候选人正在推进.
- 尽管面临挑战,全球协调的努力正在为加速开发和潜在的 iNTS 疾病预防铺平道路.
- 开发iNTS疫苗具有显著的前景,可以减少流行病地区的传染病负担.
相关概念视频
Vaccinations
52.0K
Overview
52.0K
Cancer Vaccines
1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K
Microorganisms in Medicine and Therapeutics
1.2K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.2K


